Search Within

Gopakumar Vasudeva Iyer

  1. "2024"
Formats
  1. Meeting Abstract (34)
  2. Journal Article (6)
  3. Review (1)
Groups
  1. Department of Medicine (41)
  2. Genitourinary Oncology Service (41)
  3. Solid Tumor Oncology Division (41)
  4. Graduate Medical Education (16)
  5. Department of Pathology and Laboratory Medicine (15)
  6. Human Oncology and Pathogenesis Program (14)

More Groups

People
  1. Hikmat Al-Ahmadie (15)
  2. Jonathan Rosenberg (14)
  3. David Solit (13)
  4. Eugene Pietzak (13)
  5. Dean Bajorin (10)
  6. Min Yuen Teo (9)

More People

Years
  1. 2024 (41)
Publications
  1. Journal of Clinical Oncology (18)
  2. European Journal of Cancer (5)
  3. Urologic Oncology: Seminars and Original Investigations (5)
  4. Annals of Oncology (2)
  5. European Urology (2)
  6. JCO Precision Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. Elsevier Inc. (11)
  3. Oxford University Press (3)
  4. Elsevier Science, Inc. (2)
  5. Nature Publishing Group (2)
  6. Elsevier BV (1)

More Publishers

Results (41)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Powles, T. B.; van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Maroto Rey, J. P.; Vulsteke, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • UPLIFT (ENGOT-ov67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin, a NaPi2b-directed dolaflexin antibody-drug conjugate, in platinum-resistant ovarian cancer
    Meeting Abstract

    Richardson, D.; Iyer, G.; Schmid, A.; Palma, N.; Navarro, W.; Ahnert, J. R.
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (trial in progress)
    Meeting Abstract

    Baldini, C.; Patnaik, A.; Lakhani, N.; Call, J.; Galsky, M.; Garmezy, B.; Wei, A.; Carter, L.; Powles, T.; Siefker-Radtke, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
    Meeting Abstract

    Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations
    Meeting Abstract

    Loriot, Y.; Zhang, A.; Hansen, A.; Mantia, C.; Boni, V.; Weickhardt, A.; Yu, E. Y.; Robert, M.; Iyer, G.; Murtha, A.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • A Multicenter, open-label phase 1/2 study of TYRA 300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 gene alterations (SURF301)
    Meeting Abstract

    Zhang, A.; Boni, V.; Hanson, A.; Mantia, C.; Weickhardt, A.; Yu, E.; Gupta, S.; Robert, M.; Iyer, G.; Millward, M.; more...
    European Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma
    Review

    Zhang, T.; Tan, A.; Shah, A. Y.; Iyer, G.; Morris, V.; Michaud, S.; Sridhar, S. S.
    The Oncologist (2024)

    Fulltext@MSK | Save
  • DNA damage response alterations predict for neoadjuvant chemotherapy sensitivity in muscle-invasive bladder cancer: A correlative analysis of the SWOG S1314 trial
    Journal Article

    Iyer, G.; Tangen, C. M.; Sarfaty, M.; Regazzi, A. M.; Lee, I. L.; Fong, M.; Choi, W.; Dinney, C. P. N.; Flaig, T. W.; Thompson, I. M. Jr; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Genomic and clinical characterization of non-invasive papillary urothelial carcinoma
    Meeting Abstract

    Gurbuz, B. C.; Caraballo, B.; Tallman, J.; Koll, F.; Basar, M.; Chen, J. F.; Sarungbam, J.; Sirintrapun, S. J.; Chen, Y. B.; Gopalan, A.; more...
    Laboratory Investigation (2024)

    Fulltext@MSK | Save